
From:
Sent: 22 September 2008 16:36
To:
Cc:
Subject: Final Appraisal Determination: Febuxostat for the management of hyperuricaemia in patients with gout

NHS
**National Institute for
Health and Clinical Excellence**

Midcity Place
71 High Holborn
London
WC1V 6NA

Tel: 0845 003 7780
Fax: 0845 003 7784

Sent via e-mail

22 September 2008

Dear

Final Appraisal Determination: Febuxostat for the management of hyperuricaemia in patients with gout

Thank you for your letter of 18 September. This letter represents my final assessment of the validity of your appeal points. I will not comment on points already accepted as valid, which will proceed to an appeal as previously stated.

Point 3

Having reconsidered your arguments, I agree this should go forward to be considered by an appeal panel. For guidance, I note that your appeal point is that the appraisal has been conducted so that in effect the scope was narrowed to a review of gout flares to the exclusion of management of hyperuricaemia. This is the point your submissions need to demonstrate

Point 4

I confirm I do not consider this to be a valid appeal point.

Therefore all of the points in your appeal letter with the exception of point 4 will be considered by the appeal panel.

Yours sincerely

Mark Taylor

Appeals Committee Chair